These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31643068)

  • 1. Determination of ADC Cytotoxicity in Immortalized Human Cell Lines.
    Wu S; Shah DK
    Methods Mol Biol; 2020; 2078():329-340. PubMed ID: 31643068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
    Singh AP; Sharma S; Shah DK
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
    Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
    J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
    Singh AP; Shah DK
    J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
    Burton JK; Bottino D; Secomb TW
    AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
    Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
    J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling to capture bystander-killing effect by released payload in target positive tumor cells.
    Byun JH; Jung IH
    BMC Cancer; 2019 Mar; 19(1):194. PubMed ID: 30832603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
    Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
    Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
    Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
    Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
    Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
    Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
    Salomon PL; Singh R
    Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
    Loganzo F; Tan X; Sung M; Jin G; Myers JS; Melamud E; Wang F; Diesl V; Follettie MT; Musto S; Lam MH; Hu W; Charati MB; Khandke K; Kim KS; Cinque M; Lucas J; Graziani E; Maderna A; O'Donnell CJ; Arndt KT; Gerber HP
    Mol Cancer Ther; 2015 Apr; 14(4):952-63. PubMed ID: 25646013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell killing by antibody-drug conjugates.
    Kovtun YV; Goldmacher VS
    Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors.
    Guo Y; Shen Z; Zhao W; Lu J; Song Y; Shen L; Lu Y; Wu M; Shi Q; Zhuang W; Qiu Y; Sheng J; Zhou Z; Fang L; Che J; Dong X
    Adv Sci (Weinh); 2024 Apr; 11(13):e2306309. PubMed ID: 38269648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.
    Lai KC; Deckert J; Setiady YY; Shah P; Wang L; Chari R; Lambert JM
    Pharm Res; 2015 Nov; 32(11):3593-603. PubMed ID: 25630819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
    Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
    Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.
    Okeley NM; Miyamoto JB; Zhang X; Sanderson RJ; Benjamin DR; Sievers EL; Senter PD; Alley SC
    Clin Cancer Res; 2010 Feb; 16(3):888-97. PubMed ID: 20086002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.